Azenta names Trey Martin president of Multiomics; Ginger Zhou steps down
Azenta, Inc. said William 'Trey' E. Martin III became president of its Multiomics business effective April 6, 2026, replacing Ginger Zhou, who stepped down the same day and will advise the company through November 2026. Martin's offer letter sets a $540,000 base salary and a target bonus of 80% of base, with equity awards subject to Board approval. The company said the change is aimed at accelerating execution of the Multiomics long-range plan presented at its December 2025 Investor Day, and the filing also amends change-in-control severance terms for three executive officers.
Key points
- Trey Martin became President, Multiomics, effective April 6, 2026, reporting to CEO John Marotta; he was CEO of Maravai LifeSciences from July 2023 to June 2025.
- Ginger Zhou stepped down April 6, 2026, stating no disagreement with the company; she will advise through November 2026 under a consulting fee of $103,500.
- Martin's offer letter: $540,000 base salary, 80% target bonus, target equity of about $1.7 million plus a one-time performance award of about $500,000, subject to Board approval.
- Martin's non-change-in-control severance is 12 months of salary continuation, subject to a release of claims.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.